Novartis registers Phase 3b roll-over extension study of iptacopan
The study plans to enroll 36 participants and is scheduled to start on November 16, 2026. It aims to assess the long-term safety, tolerability, and efficacy of iptacopan in patients with complement mediated diseases.
Primary source
ClinicalTrials.gov registry record, November 20, 2026
An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.
Read the source: An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases. clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation